» Articles » PMID: 9359845

N-terminal Stretch Arg2, Arg3, Arg4 and Arg5 of Human Lactoferrin is Essential for Binding to Heparin, Bacterial Lipopolysaccharide, Human Lysozyme and DNA

Overview
Journal Biochem J
Specialty Biochemistry
Date 1998 Jan 10
PMID 9359845
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Human lactoferrin (hLF), a protein involved in host defence against infection and excessive inflammation, interacts with heparin, the lipid A moiety of bacterial lipopolysaccharide, human lysozyme (hLZ) and DNA. To determine which region of the molecule is important in these interactions, solid-phase ligand binding assays were performed with hLF from human milk (natural hLF) and N-terminally deleted hLF variants. Iron-saturated and natural hLF bound equally well to heparin, lipid A, hLZ and DNA. Natural hLF lacking the first two N-terminal amino acids (Gly1-Arg2) showed reactivities of one-half, two-thirds, one-third and one-third towards heparin, lipid A, hLZ and DNA respectively compared with N-terminally intact hLF. A lack of the first three residues (Gly1-Arg2-Arg3) decreased binding to the same ligands to one-eighth, one-quarter, one-twentieth and one-seventeenth respectively. No binding occurred with a mutant lacking the first five residues (Gly1-Arg2-Arg3-Arg4-Arg5). An anti-hLF monoclonal antibody (E11) that reacts to an N-lobe epitope including Arg5 completely blocked hLF-ligand interaction. These results show that the N-terminal stretch of four consecutive arginine residues, Arg2-Arg3-Arg4-Arg5, has a decisive role in the interaction of hLF with heparin, lipid A, hLZ and DNA. The role of limited N-terminal proteolysis of hLF in its anti-infective and anti-inflammatory properties is discussed.

Citing Articles

Inflammation promotes stomach epithelial defense by stimulating the secretion of antimicrobial peptides in the mucus.

Vllahu M, Voli A, Licursi V, Zagami C, DAmore A, Traulsen J Gut Microbes. 2024; 16(1):2390680.

PMID: 39244776 PMC: 11382725. DOI: 10.1080/19490976.2024.2390680.


Lactoferrin Binds through Its N-Terminus to the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.

Babulic P, Cehlar O, Ondrovicova G, Moskalets T, Skrabana R, Leksa V Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204126 PMC: 11357225. DOI: 10.3390/ph17081021.


Anti-inflammatory peptide therapeutics and the role of sulphur containing amino acids (cysteine and methionine) in inflammation suppression: A review.

Biji C, Balde A, Nazeer R Inflamm Res. 2024; 73(7):1203-1221.

PMID: 38769154 DOI: 10.1007/s00011-024-01893-6.


The anticancer activity of bovine lactoferrin is reduced by deglycosylation and it follows a different pathway in cervix and colon cancer cells.

Ramirez-Sanchez D, Canizalez-Roman A, Leon-Sicairos N, Perez Martinez G Food Sci Nutr. 2024; 12(5):3516-3528.

PMID: 38726451 PMC: 11077203. DOI: 10.1002/fsn3.4020.


Lactoferrins in Their Interactions with Molecular Targets: A Structure-Based Overview.

Piacentini R, Boffi A, Milanetti E Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543184 PMC: 10974892. DOI: 10.3390/ph17030398.


References
1.
Nuijens J, van Berkel P, Schanbacher F . Structure and biological actions of lactoferrin. J Mammary Gland Biol Neoplasia. 1996; 1(3):285-95. DOI: 10.1007/BF02018081. View

2.
Ellison 3rd R, Giehl T . Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest. 1991; 88(4):1080-91. PMC: 295557. DOI: 10.1172/JCI115407. View

3.
Bennett R, Davis J . Lactoferrin interacts with deoxyribonucleic acid: a preferential reactivity with double-stranded DNA and dissociation of DNA-anti-DNA complexes. J Lab Clin Med. 1982; 99(1):127-38. View

4.
Metz-Boutigue M, Jolles J, Mazurier J, Schoentgen F, Legrand D, SPIK G . Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem. 1984; 145(3):659-76. DOI: 10.1111/j.1432-1033.1984.tb08607.x. View

5.
Nuijens J, Huijbregts C, van Mierlo G, Hack C . Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor. Immunology. 1987; 61(3):387-9. PMC: 1453411. View